Entera Bio Ltd. (ENTX), a clinical-stage company focused on oral peptide and protein replacement therapies, reported a net loss of $11.4 million for the year ended December 31, 2025, compared to a net loss of $9.5 million for the previous year. The company's revenue, primarily from research services, decreased from $181,000 in 2024 to $42,000 in 2025, a 77% decline. As of December 31, 2025, Entera Bio had an accumulated deficit of $125.4 million.
Research and development expenses increased by 33% to $6.0 million in 2025, driven by higher consulting fees, internal program costs, and compensation expenses, partially offset by lower material and production costs. General and administrative expenses also rose by 8% to $5.5 million, mainly due to increased consultant fees and compensation. Financial income, net, increased by 55% to $90,000, primarily due to higher interest income from bank deposits.
A key strategic development was the amended and restated collaboration agreement with OPKO Health, Inc. and OPKO Biologics Ltd. in February 2026, expanding their partnership to include the development of a long-acting PTH analog for hypoparathyroidism. In March 2025, Entera Bio entered into a collaboration and license agreement with OPKO to collaborate with respect to the preclinical and clinical development and decision making related to the Oral OXM program for the treatment of obesity, metabolic and fibrotic disorders in humans. In connection with the execution of the 2025 Collaboration Agreement, Entera Bio issued and sold to OPKO an aggregate of 3,685,226 Ordinary Shares for a purchase price of $8.0 million.
As of December 31, 2025, Entera Bio had 22 employees, with 17 in research and development and 3 in general and administrative roles. The company's cash and cash equivalents totaled $14.9 million, with $7.8 million designated for the OPKO collaboration. Management anticipates that current cash resources will fund operations through the middle of the third quarter of 2026, excluding the initiation of the Phase 3 study for EB613 in osteoporosis, which will require additional funding. The company is actively exploring financing alternatives, including equity offerings, debt financing, and strategic collaborations. The company's independent registered public accounting firm has expressed substantial doubt about its ability to continue as a going concern.
About Entera Bio Ltd.
Entera Bio Ltd. develops oral peptide and protein replacement therapies targeting chronic conditions like osteoporosis and hypoparathyroidism. Utilizing its proprietary N-Tab platform, the company aims to replace injectable treatments with convenient daily tablets. Its pipeline includes first-in-class oral PTH and GLP programs, focusing on underserved markets and leveraging strategic collaborations to advance innovative, patient-friendly therapeutics.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.